BRPI0815564B8 - anticorpos que inibem a dimerização de c-met e usos dos mesmos, hibridoma de murino, anticorpo, ácido nucleico isolado, vetor, método para produção de anticorpo, composição, uso e método de diagnóstico in vitro de enfermidades induzidas por uma superexpressão ou subexpressão do receptor de c-met - Google Patents

anticorpos que inibem a dimerização de c-met e usos dos mesmos, hibridoma de murino, anticorpo, ácido nucleico isolado, vetor, método para produção de anticorpo, composição, uso e método de diagnóstico in vitro de enfermidades induzidas por uma superexpressão ou subexpressão do receptor de c-met

Info

Publication number
BRPI0815564B8
BRPI0815564B8 BRPI0815564A BRPI0815564A BRPI0815564B8 BR PI0815564 B8 BRPI0815564 B8 BR PI0815564B8 BR PI0815564 A BRPI0815564 A BR PI0815564A BR PI0815564 A BRPI0815564 A BR PI0815564A BR PI0815564 B8 BRPI0815564 B8 BR PI0815564B8
Authority
BR
Brazil
Prior art keywords
met
antibody
antibodies
inhibit
underexpression
Prior art date
Application number
BRPI0815564A
Other languages
English (en)
Portuguese (pt)
Inventor
Goetsch Liliane
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38871713&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0815564(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BRPI0815564A2 publication Critical patent/BRPI0815564A2/pt
Publication of BRPI0815564B1 publication Critical patent/BRPI0815564B1/pt
Publication of BRPI0815564B8 publication Critical patent/BRPI0815564B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
BRPI0815564A 2007-07-12 2008-07-10 anticorpos que inibem a dimerização de c-met e usos dos mesmos, hibridoma de murino, anticorpo, ácido nucleico isolado, vetor, método para produção de anticorpo, composição, uso e método de diagnóstico in vitro de enfermidades induzidas por uma superexpressão ou subexpressão do receptor de c-met BRPI0815564B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92978907P 2007-07-12 2007-07-12
EP07301231A EP2014681A1 (en) 2007-07-12 2007-07-12 Novel antibodies inhibiting c-met dimerization, and uses thereof
US2063908P 2008-01-11 2008-01-11
PCT/EP2008/059026 WO2009007427A2 (en) 2007-07-12 2008-07-10 Novel antibodies inhibiting c-met dimerization, and uses thereof

Publications (3)

Publication Number Publication Date
BRPI0815564A2 BRPI0815564A2 (pt) 2015-02-18
BRPI0815564B1 BRPI0815564B1 (pt) 2020-01-21
BRPI0815564B8 true BRPI0815564B8 (pt) 2021-05-25

Family

ID=38871713

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815564A BRPI0815564B8 (pt) 2007-07-12 2008-07-10 anticorpos que inibem a dimerização de c-met e usos dos mesmos, hibridoma de murino, anticorpo, ácido nucleico isolado, vetor, método para produção de anticorpo, composição, uso e método de diagnóstico in vitro de enfermidades induzidas por uma superexpressão ou subexpressão do receptor de c-met

Country Status (35)

Country Link
US (6) US8329173B2 (enExample)
EP (6) EP2014681A1 (enExample)
JP (4) JP5562844B2 (enExample)
KR (4) KR101701686B1 (enExample)
CN (4) CN101981054B (enExample)
AR (4) AR067517A1 (enExample)
AU (1) AU2008274171B2 (enExample)
BR (1) BRPI0815564B8 (enExample)
CA (4) CA2888691C (enExample)
CL (1) CL2008002015A1 (enExample)
CO (1) CO6170364A2 (enExample)
CY (1) CY1116608T1 (enExample)
DK (1) DK2188312T3 (enExample)
ES (5) ES2686335T3 (enExample)
HR (1) HRP20150887T1 (enExample)
HU (1) HUE026026T2 (enExample)
IL (5) IL203114A (enExample)
MA (1) MA31977B1 (enExample)
ME (1) ME02341B (enExample)
MX (3) MX345391B (enExample)
MY (1) MY158756A (enExample)
NZ (4) NZ599959A (enExample)
PA (1) PA8789201A1 (enExample)
PH (3) PH12018502039A1 (enExample)
PL (1) PL2188312T3 (enExample)
PT (1) PT2188312E (enExample)
RS (1) RS54197B1 (enExample)
RU (1) RU2552161C2 (enExample)
SA (1) SA08290423B1 (enExample)
SG (1) SG183015A1 (enExample)
SI (1) SI2188312T1 (enExample)
TN (1) TN2010000016A1 (enExample)
TW (4) TWI549965B (enExample)
WO (1) WO2009007427A2 (enExample)
ZA (1) ZA201000966B (enExample)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2143441A1 (en) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
AR074439A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
US9469691B2 (en) 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
US20140112911A9 (en) * 2008-12-02 2014-04-24 Liliane Goetsch Novel anti-cmet antibody
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
MX2011010169A (es) 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-1/anti-c-met.
KR20110124369A (ko) 2009-04-07 2011-11-16 로슈 글리카트 아게 이중특이적 항­ｅｒｂｂ­3／항­ｃ­ｍｅｔ 항체
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
KR101748707B1 (ko) 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
BR112012022672B1 (pt) 2010-03-10 2020-04-14 Genmab As anticorpo monoclonal, sequência de nucleotídeos, vetor de expressão, célula hospedeira procariótica recombinante, composição farmacêutica, uso do anticorpo, métodos para produzir um anticorpo, para detectar a presença de c-met em uma amostra, e, kit para detectar a presença de c-met em uma amostra
EP2808344A1 (en) * 2010-06-01 2014-12-03 Monash University Antibodies directed to the receptor tyrosine kinase c-Met
EP2402370A1 (en) * 2010-06-29 2012-01-04 Pierre Fabre Médicament Novel antibody for the diagnosis and/or prognosis of cancer
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
DK2612151T3 (en) 2010-08-31 2017-10-02 Genentech Inc BIOMARKETS AND METHODS OF TREATMENT
WO2012030842A2 (en) * 2010-09-03 2012-03-08 Academia Sinica Anti-c-met antibody and methods of use thereof
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
RU2013125457A (ru) 2010-11-03 2014-12-10 Арджен-Икс Бв Комбинация антител против с-мет
US20130236467A1 (en) 2010-11-24 2013-09-12 Jeremy Griggs Multispecific antigen binding proteins targeting hgf
KR101444837B1 (ko) 2011-06-03 2014-09-30 한국생명공학연구원 ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도
IN2014CN00414A (enExample) * 2011-06-23 2015-04-03 Ablynx Nv
IN2014CN00373A (enExample) 2011-06-23 2015-04-03 Ablynx Nv
WO2013003680A1 (en) * 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
MX2014002289A (es) 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Anticuerpos fc especificos en tandem.
MX2014002990A (es) 2011-09-19 2014-05-21 Genentech Inc Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf.
WO2013043452A1 (en) 2011-09-20 2013-03-28 Eli Lilly And Company Anti-c-met antibodies
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
CA2850261C (en) 2011-09-30 2021-04-20 Ablynx Nv C-met immunoglobulin single variable domains
KR101865223B1 (ko) * 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
KR20130037153A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 및 그의 용도
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
EP2773660A2 (en) 2011-11-03 2014-09-10 Argen-X B.V. Chimeric human-camel antigens and their use
SG11201402485UA (en) 2011-11-21 2014-06-27 Genentech Inc Purification of anti-c-met antibodies
US20150147274A1 (en) 2011-12-02 2015-05-28 Cancer Research Technology Limited Antibodies against hgf - receptor and uses
KR101910601B1 (ko) 2011-12-22 2018-10-23 삼성전자주식회사 면역원성이 제거된 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
US9376485B2 (en) 2012-02-29 2016-06-28 The Brigham And Women's Hospital, Inc. Neutralizing antibody for epstein barr virus-associated disease
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US10377827B2 (en) 2012-06-21 2019-08-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
KR101938698B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｃｂｌ의 항 ｃ－ｍｅｔ 항체 적용 대상 환자 선별을 위한 바이오마커로서의 용도
KR101938699B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｌｒｉｇ１의 항 ｃ―ｍｅｔ 항체 적용 대상 환자 선별을 위한 용도
AU2013302441B2 (en) * 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
EP2894472A4 (en) * 2012-09-05 2016-03-30 Jsr Corp METHOD OF SCREENING MATERIAL FOR EPITHELIAL CONSERVATION OF CELLS
RS58921B1 (sr) 2012-10-12 2019-08-30 Medimmune Ltd Pirolobenzodiazepini i njihovi konjugati
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
WO2014074907A1 (en) * 2012-11-09 2014-05-15 Indi Molecular, Inc. C-met-specific capture agents, compositions, and methods of using and making
KR101911048B1 (ko) 2013-01-29 2018-10-24 삼성전자주식회사 ｐ５３ 활성화제 및 ｃ－Ｍｅｔ 억제제를 포함하는 병용 투여용 약학 조성물
KR20150118159A (ko) 2013-02-22 2015-10-21 에프. 호프만-라 로슈 아게 암의 치료 방법 및 약물 내성의 예방 방법
TW201444872A (zh) 2013-03-06 2014-12-01 Merrimack Pharmaceuticals Inc 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體
KR102066319B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
KR102139607B1 (ko) * 2013-04-01 2020-07-30 삼성전자주식회사 항 c-Met 항체 및 FGFR 저해제를 포함하는 병용 투여용 약학 조성물
KR102089591B1 (ko) 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
WO2015031614A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015031626A1 (en) 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
EP3146071B1 (en) 2014-05-23 2020-09-02 F. Hoffmann-La Roche AG Mit biomarkers and methods using the same
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
WO2016042412A1 (en) 2014-09-16 2016-03-24 Symphogen A/S Anti-met antibodies and compositions
WO2016053610A1 (en) * 2014-10-03 2016-04-07 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
JP2018503596A (ja) 2014-10-03 2018-02-08 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｔｄｐ−４３の病理学的形態に対する抗体及びその使用
WO2016079194A1 (en) * 2014-11-20 2016-05-26 Stichting Katholieke Universiteit A novel auto-active and intracellular mutant of met
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
JP6862343B2 (ja) 2014-12-19 2021-04-21 アブリンクス エン．ヴェー． システイン結合ナノボディダイマー
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
EP3270918A4 (en) 2015-03-16 2018-10-24 Celldex Therapeutics, Inc. Anti-met antibodies and methods of use thereof
AU2016239844B2 (en) 2015-04-02 2021-05-13 Ablynx N.V. Bispecific CXCR4-CD-4 polypeptides with potent anti-HIV activity
TW201709932A (zh) * 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
US20190194345A1 (en) * 2015-10-05 2019-06-27 University Of Virginia Patent Foundation Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
CA3003759A1 (en) 2015-11-03 2017-05-11 Merck Patent Gmbh Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
EP3436480A4 (en) * 2016-03-30 2019-11-27 Musc Foundation for Research Development METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
RU2740996C2 (ru) 2016-05-17 2021-01-22 Эббви Байотерапьютикс Инк. КОНЪЮГАТЫ АНТИТЕЛА К cMet И ЛЕКАРСТВЕННОГО СРЕДСТВА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP7120989B2 (ja) * 2016-07-06 2022-08-17 セルジーン コーポレイション 低免疫原性を有する抗体及びその使用
US20200023072A1 (en) 2016-10-11 2020-01-23 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
US11525004B2 (en) 2017-07-20 2022-12-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Recombinant CD123-binding antibodies
KR102194025B1 (ko) 2017-12-15 2020-12-22 경북대학교 산학협력단 CD44v6에 결합하는 펩타이드 및 이의 용도
WO2019117691A1 (ko) * 2017-12-15 2019-06-20 경북대학교 산학협력단 CD44v6에 결합하는 펩타이드 및 이의 용도
MX2020009989A (es) * 2018-03-24 2020-10-14 Regeneron Pharma Animales no humanos geneticamente modificados para generar anticuerpos terapeuticos contra complejos peptidos-mhc, metodos de elaboracion y usos de estos.
KR20210016562A (ko) 2018-05-23 2021-02-16 에이디씨 테라퓨틱스 에스에이 분자 애쥬번트
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN109541221B (zh) * 2018-10-24 2022-03-22 益善生物技术股份有限公司 一种c-Met特异性抗体、组合物及试剂盒
CN115605491A (zh) 2019-04-05 2023-01-13 刘扶东（Us） 抗唾液酸酶的糖类、其制造方法及用途
MX2022002886A (es) 2019-09-16 2022-04-06 Regeneron Pharma Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet.
EP4146241A4 (en) 2020-05-08 2024-06-05 Academia Sinica CHIMERIC INFLUENZA VACCINES
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
US20240117061A1 (en) * 2020-12-16 2024-04-11 Wuhan Yzy Biopharma Co., Ltd. Anti-bcma antibody, preparation method therefor and application thereof
CN112679614B (zh) * 2021-01-15 2022-08-16 广东安普泽生物医药股份有限公司 用于特异性结合rankl靶向治疗药物的抗体及其用途
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN112946279A (zh) * 2021-03-17 2021-06-11 扬州大学 一种基于油水界面自组装的三明治sers免疫传感器检测宫颈癌患者血清生物标志物方法
MX2023011733A (es) 2021-04-06 2023-10-13 Abbvie Biotherapeutics Inc Metodos para el tratamiento del carcinoma de pulmon de celulas no peque?as usando telisotuzumab vedotin.
JP7580568B2 (ja) 2021-04-12 2024-11-11 アカデミア シニカ 改良されたコロナウイルスワクチン
UY39743A (es) 2021-04-29 2022-11-30 Abbvie Inc Conjugados de anticuerpo anti-c-met y fármaco
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
KR20240095442A (ko) 2021-11-03 2024-06-25 항저우 디에이씨 바이오테크 씨오, 엘티디 항체의 특이적 접합
TW202342511A (zh) * 2021-12-27 2023-11-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
TW202434637A (zh) * 2022-12-20 2024-09-01 美商翰森生物有限責任公司 抗體、抗原結合片段及其醫藥用途
EP4568709A2 (en) 2023-04-08 2025-06-18 Rock Biomedical Inc. Methods and compositions for targeted delivery by polymersomes
WO2025025434A1 (zh) * 2023-08-02 2025-02-06 百泰生物药业有限公司 EGFR/c-Met双特异性抗体及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2840250C2 (de) 1978-09-15 1983-01-20 Siemens AG, 1000 Berlin und 8000 München Schaltungsanordnung für eine leitungsgespeiste Lautfernsprechstation
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
ES2172149T3 (es) * 1997-04-14 2002-09-16 Micromet Ag Nuevo metodo para la produccion de receptores de antigeno anti-humano y sus usos.
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
AU2003215365A1 (en) * 2002-02-21 2003-09-09 Duke University Treatment methods using anti-cd22 antibodies
CA2516236A1 (en) * 2003-02-13 2004-08-26 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
US9416187B2 (en) * 2003-05-09 2016-08-16 Duke University CD-20 specific antibodies and methods of employing same
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CA2548282A1 (en) * 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
AU2005267720B2 (en) * 2004-08-05 2012-02-23 Genentech, Inc. Humanized anti-cmet antagonists
US20060094059A1 (en) 2004-09-22 2006-05-04 Odyssey Thera, Inc. Methods for identifying new drug leads and new therapeutic uses for known drugs
US8080638B2 (en) * 2005-02-10 2011-12-20 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
EP1874816A4 (en) 2005-04-26 2010-08-25 Medimmune Inc MODULATION OF THE ANTIBODY EFFECTOR FUNCTION BY "HINGE" DOMENGINE ENGINEERING
SI1915398T1 (sl) 2005-07-18 2016-07-29 Amgen Inc. Humana nevtralizacijska protitelesa proti b7rp1
EP1913027B1 (en) 2005-07-28 2015-03-04 Novartis AG M-csf specific monoclonal antibody and uses thereof
US8388958B2 (en) 2006-02-06 2013-03-05 Metheresis Translational Research Sa Anti-MET monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
MX2008012485A (es) 2006-03-30 2008-10-10 Novartis Ag Composiciones y metodos de uso para anticuerpos de c-met.
EP2143441A1 (en) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
WO2010064089A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Novel anti-cmet antibody

Also Published As

Publication number Publication date
EP2188312B1 (en) 2015-05-27
KR20160019975A (ko) 2016-02-22
NZ599959A (en) 2013-11-29
IL223109B (en) 2019-06-30
US8889832B2 (en) 2014-11-18
TW201605891A (zh) 2016-02-16
SA08290423B1 (ar) 2013-12-23
JP2014113154A (ja) 2014-06-26
HK1193619A1 (zh) 2014-09-26
CN103183739A (zh) 2013-07-03
US20140010818A1 (en) 2014-01-09
MX353449B (es) 2018-01-08
ES2542059T3 (es) 2015-07-30
ES2686335T3 (es) 2018-10-17
US20130272957A1 (en) 2013-10-17
CA2694418C (en) 2018-03-27
TW201437231A (zh) 2014-10-01
AR109659A2 (es) 2019-01-09
IL203114A (en) 2015-03-31
TWI592427B (zh) 2017-07-21
CN103509113A (zh) 2014-01-15
SG183015A1 (en) 2012-08-30
CA2982484A1 (en) 2009-01-15
EP2535356A1 (en) 2012-12-19
TN2010000016A1 (en) 2011-09-26
ES2686693T3 (es) 2018-10-19
CA2981821A1 (en) 2009-01-15
EP2535357A1 (en) 2012-12-19
BRPI0815564B1 (pt) 2020-01-21
WO2009007427A2 (en) 2009-01-15
KR20100044212A (ko) 2010-04-29
ZA201000966B (en) 2011-02-23
HK1193620A1 (zh) 2014-09-26
PH12018502040A1 (en) 2019-08-19
TWI602829B (zh) 2017-10-21
HUE026026T2 (en) 2016-05-30
JP2014113155A (ja) 2014-06-26
KR101701685B1 (ko) 2017-02-01
KR101719084B1 (ko) 2017-03-22
PA8789201A1 (es) 2009-08-26
RU2552161C2 (ru) 2015-06-10
AR109535A2 (es) 2018-12-19
US8329173B2 (en) 2012-12-11
MY158756A (en) 2016-11-15
BRPI0815564A2 (pt) 2015-02-18
US20130273060A1 (en) 2013-10-17
CN101981054A (zh) 2011-02-23
PH12018502039A1 (en) 2019-08-19
IL223105A0 (en) 2012-12-31
HK1149024A1 (en) 2011-09-23
WO2009007427A3 (en) 2009-04-09
ME02341B (me) 2015-12-31
EP2535357B1 (en) 2018-08-08
AR109660A2 (es) 2019-01-09
AU2008274171A1 (en) 2009-01-15
CA2888691A1 (en) 2009-01-15
RS54197B1 (sr) 2015-12-31
CA2888691C (en) 2023-01-03
US9107907B2 (en) 2015-08-18
CN101981054B (zh) 2015-04-15
CY1116608T1 (el) 2017-03-15
IL223106A0 (en) 2012-12-31
RU2010104633A (ru) 2011-08-20
CN103509112A (zh) 2014-01-15
JP5889924B2 (ja) 2016-03-22
PL2188312T3 (pl) 2016-01-29
DK2188312T3 (en) 2015-08-03
JP5889923B2 (ja) 2016-03-22
US8871909B2 (en) 2014-10-28
EP2014681A1 (en) 2009-01-14
ES2678495T3 (es) 2018-08-13
TW201605892A (zh) 2016-02-16
IL223109A0 (en) 2012-12-31
CL2008002015A1 (es) 2008-11-21
KR101625234B1 (ko) 2016-05-30
CN103509112B (zh) 2015-10-21
US20150252114A1 (en) 2015-09-10
CN103509113B (zh) 2015-10-21
KR101701686B1 (ko) 2017-02-01
EP2415785A1 (en) 2012-02-08
JP2010532982A (ja) 2010-10-21
CA2982484C (en) 2021-06-01
CO6170364A2 (es) 2010-06-18
EP2188312A2 (en) 2010-05-26
US8871910B2 (en) 2014-10-28
CN103183739B (zh) 2016-08-17
TWI602830B (zh) 2017-10-21
AR067517A1 (es) 2009-10-14
SI2188312T1 (sl) 2015-09-30
EP2415784A1 (en) 2012-02-08
PH12018502038A1 (en) 2019-08-19
EP2535356B1 (en) 2018-06-13
US20100115639A1 (en) 2010-05-06
CA2981821C (en) 2020-07-28
IL223106B (en) 2020-06-30
PT2188312E (pt) 2015-10-05
NZ613716A (en) 2015-01-30
CA2694418A1 (en) 2009-01-15
IL223105B (en) 2020-02-27
US20130280257A1 (en) 2013-10-24
JP5562844B2 (ja) 2014-07-30
JP2014113153A (ja) 2014-06-26
IL223108B (en) 2019-06-30
TWI549965B (zh) 2016-09-21
JP5889925B2 (ja) 2016-03-22
ES2693542T3 (es) 2018-12-12
MX341012B (es) 2016-08-03
KR20160019974A (ko) 2016-02-22
NZ599958A (en) 2013-11-29
AU2008274171B2 (en) 2014-02-27
NZ583041A (en) 2012-06-29
IL223108A0 (en) 2012-12-31
EP2415785B1 (en) 2018-04-25
EP2415784B1 (en) 2018-06-13
HRP20150887T1 (hr) 2015-09-25
TW200911828A (en) 2009-03-16
MX345391B (es) 2017-01-27
KR20150070451A (ko) 2015-06-24
MA31977B1 (fr) 2011-01-03

Similar Documents

Publication Publication Date Title
BRPI0815564B8 (pt) anticorpos que inibem a dimerização de c-met e usos dos mesmos, hibridoma de murino, anticorpo, ácido nucleico isolado, vetor, método para produção de anticorpo, composição, uso e método de diagnóstico in vitro de enfermidades induzidas por uma superexpressão ou subexpressão do receptor de c-met
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
FI3036258T3 (fi) Immunoreseptorin modulointi syövän ja virusinfektioiden hoitamiseksi
BR112014006390A2 (pt) anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
BR112022006001A2 (pt) Imunoconjugado, composto de 8-amido-2-aminobenzazepina-ligante, composto de 5-amino-pirazoloazepina-ligante, composto de aminoquinolina-ligante, uso de um imunoconjugado e métodos para tratar câncer e para preparar um imunoconjugado
BR112014007721A2 (pt) processos para preparar compostos úteis como inibidores de atr quinase
TN2010000092A1 (en) Humanized cxcr5 antidodies, derivatives thereof and their uses
BR112013010310A2 (pt) inibidores de acetil-coa carboxilase de lactama n1/n2
BRPI0923786C8 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
BRPI0506726B8 (pt) anticorpo monoclonal específico para m-csf e usos deste
BR112018015238A2 (pt) conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição
BR112012016992A2 (pt) "funcionalidade que se liga a uma interface de contato assimétrico de um recpetor de tirosina quinase (rtk), hibridoma, composição farmacêutica, uso de uma quantidade efixaz da funcionalidade, método para identificar uma funcionalidade que se liga a uma interface de contato assimétrico de um receptor de tirosina quinase (rtk), e, molécula pequena".
BR112012028445A2 (pt) compostos de heteroarila bicíclica como moduladores de gpr119
BR112014008775A2 (pt) camundongo de cadeia pesada de imunoglobulina restrita
BR112012018951A8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
EA201100779A1 (ru) Композиции антител к cxcr1 и способы их применения
BR112012030318A2 (pt) composto específicos de anti-cd160 para o tratamento de transtornos oculares com base em neoangiogênese
BR112012014984A2 (pt) anticorpos dirigidos contra o receptor da transferrina e as suas utilizacoes para a imunoterapia dos tumores que dependem do ferro
AR073459A1 (es) Composiciones de dominios variables de anticuerpos monovalentes para la union de cd28 y metodos de uso
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
BR112012024786A2 (pt) anticorpos humanizados il-25
WO2007018671A3 (en) Compositions and methods for treating conditions related to ephrin signaling with cupredoxins

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/01/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/07/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF